DEF: Ainos Sets 2025 Annual Meeting, Proposes Stock Awards

Ainos, Inc. announced its 2025 Annual Meeting of Stockholders to be held on November 7, 2025, to elect directors, ratify auditors, and approve a significant special stock award reservation.

Summary

• Ainos, Inc. will hold its 2025 Annual Meeting of Stockholders on November 7, 2025, at 5:30 p.m. Taiwan Standard Time.
• The record date for voting eligibility is September 17, 2025, with 4,771,184 shares of Common Stock outstanding and entitled to vote.
• Key proposals include the election of seven directors, ratification of YCM CPA INC. as the independent registered public accounting firm for fiscal year 2024, and approval to reserve up to 950,000 shares of common stock for special stock awards outside the existing 2023 Stock Incentive Plan.
• The Board recommends voting FOR all proposals.
• The company reported significant net losses: $(14,863,161) in 2024, $(13,770,549) in 2023, $(14,006,690) in 2022, and $(3,888,661) in 2021.
• Total Shareholder Return (TSR) based on a hypothetical $100 investment was negative in recent years: $(96) in 2024, $(84) in 2023, $(76) in 2022, but positive $394 in 2021.
• Executive compensation for CEO Chun-Hsien Tsai in 2024 included a salary of $122,517, a bonus of $115,313, and stock awards of $63,692, totaling $301,522. His "Compensation Actually Paid" was $20,669.
• The company engaged in several related party transactions, including a patent license agreement with Taiwan Carbon Nano Technology Corporation (TCNT) for 5,500,000 shares of common stock, and a $9,000,000 convertible note and warrant agreement with ASE Test, Inc.
• TCNT is identified as the controlling shareholder, holding a majority interest in Ainos KY and direct ownership, giving it majority voting power in Ainos, Inc.

Sentiment

Score: 3

Explanation: The filing reveals significant ongoing net losses and negative shareholder returns, which are major concerns. While there are positive developments like securing patent licenses and recent capital infusion, the heavy reliance on related party transactions and the proposed stock awards for dilution raise caution. The company's clinical-stage nature explains losses, but the lack of alignment between executive pay and net income, coupled with negative TSR, suggests poor financial performance for shareholders.

Positives

• Secured an exclusive, irrevocable, and perpetual license for gas sensor and medical device patents from TCNT, bolstering AI Nose and POCT technologies.
• Successfully paid off the remaining $270,000 principal amount of the working capital promissory note from Ainos KY on October 7, 2024.
• Received the full $9,000,000 payment from ASE Test, Inc. for convertible notes and warrants by December 31, 2024, providing capital.
• Increased monthly salaries for CEO Chun-Hsien Tsai and CFO Hsin-Liang Lee effective September 1, 2024, potentially indicating confidence in leadership.
• The Board has three independent directors, and all Audit Committee members qualify as financial experts, enhancing corporate governance.

Negatives

• The company reported substantial net losses for four consecutive years: $(14,863,161) in 2024, $(13,770,549) in 2023, $(14,006,690) in 2022, and $(3,888,661) in 2021.
• Total Shareholder Return (TSR) has been negative in recent years, indicating poor stock performance.
• Executive compensation is not aligned with net income, as the company continues to incur substantial operating losses.
• The company relies heavily on related party transactions for significant operational aspects, including patent licenses, product development, and past working capital advances.
• The proposed reservation of up to 950,000 shares for special stock awards, outside the existing incentive plan, could lead to significant dilution for existing shareholders.
• The company prepaid NT$5 million (USD$162,840) to TCNT for five years of product development, which might tie up cash.
• The company is paying a monthly fee of $95,000 (plus 5% indirect tax) for non-exclusive use of certain patents related to VOC and POCT technologies, which increased overall expenses.

Risks

• Financial Performance: Continued substantial operating losses and negative net income pose a significant risk to financial stability and future profitability.
• Shareholder Dilution: The proposed reservation of up to 950,000 shares for special stock awards, and the issuance of 5,500,000 shares to TCNT for patent licenses, could lead to significant dilution for existing shareholders.
• Reliance on Related Parties: Extensive reliance on related parties like TCNT and Ainos KY for patent licenses, product development, and past working capital advances could create conflicts of interest and impact independent decision-making.
• Control by Related Parties: TCNT's majority interest in Ainos KY and direct ownership gives it controlling voting power, potentially limiting the influence of other shareholders.
• Liquidity and Capital Requirements: As a clinical-stage biotechnology and medical device company, the company has substantial future capital requirements to continue R&D and advance drug candidates, indicating potential future capital raises.
• Stock Price Volatility: The negative Total Shareholder Return in recent years suggests volatility and potential for further decline in stock value.
• Regulatory Risk: The company's products, such as COVID-19 test kits, are subject to emergency use authorizations (EUAs) which can be revoked or expire, impacting sales and marketing agreements.

Future Outlook

The company is a clinical-stage biotechnology and medical device company with substantial future capital requirements for research and development activities and advancing drug candidates. It aims to attract and retain key personnel through equity interests and incentive compensation, aligning interests with shareholders.

Management Comments

• Our executive compensation is designed to (1) attract, motivate and retain talented executives with total compensation that is competitive in our industry; (2) align the interests of our executives and our stockholders; and (3) award behavior which results in optimizing the commercial potential of our development program.
• As a clinical stage biotechnology and medical device company, we have incurred substantial operating losses, principally from expenses associated with the Company’s research and development programs, clinical trials conducted in connection with the Company’s drug candidates, and applications and submissions to regulatory authorities.
• Net income is not a performance measure we use in determining executive compensation. We use a number of corporate goals that may include research and development, regulatory, manufacturing, organization and financial goals which we believe are important to building stockholder value.

Industry Context

The company operates in the biotechnology and medical device sectors, characterized by high R&D costs, long development cycles, and significant capital requirements. The focus on AI Nose and point-of-care testing (POCT) technologies aligns with broader industry trends towards diagnostics and personalized medicine. The reliance on emergency use authorizations for COVID-19 test kits highlights the dynamic regulatory environment in this space. The negative net income and TSR are common challenges for clinical-stage companies that are heavily investing in R&D before commercialization.

Comparison to Industry Standards

• The company's sustained net losses and negative Total Shareholder Return are typical for early-stage biotechnology and medical device companies that are heavily investing in research and development. For example, many pre-revenue biotech firms often report significant losses for years as they advance drug candidates through clinical trials, similar to Ainos's situation.
• The use of stock awards and options as a significant component of executive compensation is a common practice in the biotech industry to align management incentives with long-term shareholder value, despite the current negative TSR.
• The reliance on related party transactions for intellectual property and product development, such as with TCNT, is not uncommon in smaller or emerging companies, especially those with complex corporate structures or strategic alliances, but it warrants close scrutiny for potential conflicts of interest compared to larger, more established industry players.
• The capital raise through convertible notes and warrants, like the $9 million from ASE Test, is a standard financing mechanism for growth-stage companies in the sector, often used to fund R&D without immediate equity dilution at potentially low valuations.

Management Changes

Corporate Governance

Related Party Transactions

• Patent License Agreement with TCNT: On August 6, 2024, the company entered into an exclusive, irrevocable, and perpetual license agreement with TCNT for certain invention patents and patent applications related to gas sensors and medical devices, in exchange for 5,500,000 shares of Common Stock.
• Working Capital Advances from Ainos KY: Ainos KY provided an $800,000 promissory note in March 2022. $530,000 was paid off in 2023, and the remaining $270,000 was paid off on October 7, 2024, with accrued interest.
• Convertible Note and Warrant Purchase Agreement with ASE Test, Inc.: On May 3, 2024, the company entered into an agreement with ASE Test, Inc. (a shareholder of Ainos KY) for $9,000,000 in 6% convertible promissory notes and warrants for 500,000 shares of common stock at $4.50/share. The full payment was received by December 31, 2024.
• Ainos COVID-19 Test Kits Sales and Marketing Agreement with Ainos KY: On June 14, 2021, the company entered into an exclusive agreement with Ainos KY to serve as the master sales and marketing agent for COVID-19 test kits developed by TCNT. Costs incurred were nil in 2024 and $46,635 in 2023.
• Product Development Agreement with TCNT: Effective August 1, 2021, development expenses were $413,324 in 2024 and $368,372 in 2023. An addendum on January 9, 2024, involved a prepaid fee of NT$5 million (USD$162,840) for five years of development.
• Patent Use Fees to TCNT: The company paid TCNT a monthly fee of $95,000 (plus 5% indirect tax) for non-exclusive use of VOC and POCT patents from January to September 2024. A third addendum on October 16, 2024, established a monthly fee of $50,000 (plus 5% indirect tax) for twelve months for exclusive use of VOC, POCT, and nitrogen-oxygen separation machine technologies. Total license fees paid to TCNT by December 31, 2024, amounted to $1,005,000 (plus 5% indirect tax).
• Controlling Shareholder: TCNT holds a majority share of Ainos KY, which holds majority voting power of the company as of December 31, 2024.

Stakeholder Impact

• Shareholders: Potential dilution from the proposed 950,000 special stock awards and the 5,500,000 shares issued to TCNT. Negative TSR and ongoing losses impact shareholder value. Voting on key corporate governance matters and executive compensation.
• Employees/Management: Benefit from potential special stock awards and existing stock incentive plans, aligning their interests with company performance. Salary increases for CEO and CFO.
• Creditors: The $9,000,000 convertible notes issued to ASE Test represent a new debt obligation, though convertible to equity. The payoff of the Ainos KY promissory note reduces one debt.
• Partners (TCNT, Ainos KY, ASE Test): Deepened strategic and financial ties through patent licenses, product development agreements, and convertible notes, reinforcing their influence and ownership.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on November 7, 2025, to vote on director elections, auditor ratification, and special stock awards.
• Elect seven nominated directors.
• Ratify the appointment of YCM CPA INC. as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• Approve the reservation of up to 950,000 shares of common stock as special stock awards.
• Potentially adjourn the Annual Meeting if necessary to solicit additional proxies.
• File a current report on Form 8-K with the SEC within four business days after the Annual Meeting to disclose voting results.
• Continue research and development activities and advance drug candidates through various development stages.
• Administer the Special Stock Awards, determining recipients and types of awards.

Key Dates

Recommendation

The company has a history of significant and increasing net losses, with a negative Total Shareholder Return over recent years. While it is a clinical-stage company, the lack of alignment between executive compensation and net income, coupled with substantial dilution from related party transactions (5.5 million shares for patents) and proposed special stock awards (950,000 shares), raises concerns about shareholder value protection. The heavy reliance on related parties for critical operations and financing, where one related party (TCNT) is also the controlling shareholder, presents potential governance risks and conflicts of interest. The current financial performance and governance structure suggest a high-risk investment with limited near-term upside for public shareholders.

Keywords

Proxy Statement, Annual Meeting, Stock Awards, Corporate Governance, Executive Compensation, Related Party Transactions, Biotechnology, Medical Device, SEC Filing, Shareholder Vote, Nasdaq Listing Rule 5635(c), Patent License, Convertible Notes, TCNT, Ainos KY, ASE Test, Net Loss, Total Shareholder Return, Director Election, Auditor Ratification, Dilution